Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal.
At the same time the European Medicines Agency, which oversees drug safety across the bloc, warned of bigger than expected staff losses and cuts in some activities as a result of having to move from London to Amsterdam due to Brexit.
Europe’s equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019.
The announcements show how the highly regulated pharmaceuticals sector is feeling the impact of Britain’s looming departure from the EU.
The moves by Sanofi and Novartis follow similar action by AstraZeneca, which said last month it would increase stockpiles of drugs that could be affected by Brexit by around 20 percent.
Roche, the world’s biggest maker of cancer medicines, also said it was taking “appropriate action” to review its stock levels in order to protect supplies to patients.
Britain’s largest drugmaker, GlaxoSmithKline, said last week it was taking steps to secure the supply of its medicines and vaccines ahead of the UK’s departure from the EU, without going into details.
Supplies of thousands of medicines are at risk of disruption if Britain leaves the EU without a deal, forcing manufacturers to prepare duplicate product testing and licensing arrangements to ensure their drugs stay on the market.
More than 2,600 drugs have some stage of manufacture in Britain and 45 million patient packs are supplied from the UK to other European countries each month, while another 37 million flow in the opposite direction, industry figures show.
Leading drugmakers have long been vocal in their concerns about Brexit and the need for the pharmaceuticals sector to stay within the European regulatory system.
British lawmakers have also called for an agreement that allows the country to have continued participation in the European medicines regulatory framework, but it remains unclear how this will play out in the broader EU negotiations.
Sanofi said it was confident its stockpiling measures would ensure British patients had access to its treatments after Britain leaves the EU, regardless of whether a deal over its future relations with the bloc is in place.
“The uncertainty in the Brexit negotiations means that Sanofi has always been planning for a no deal scenario,” a spokesman with the French drugmaker said in an emailed statement.
“We have made arrangements for additional warehouse capacity in order to stockpile our products in the UK and increase UK-based resources to prepare for any changes to customs or regulatory processes.”
Novartis said it planned to hold increased inventories in Britain across its portfolio of medicines from both Novartis itself and Sandoz, the Swiss company’s generic drugs division.
“We have apprised officials and ministers of our preparedness plans and status, including plans to increase our UK inventory holding,” Novartis said.
The European Medicines Agency has warned drugmakers they needed to be ready for a possible hard Brexit in 2019. It has also expressed “serious concerns” over the availability of some 108 medicines that are manufactured exclusively in the UK.
By Matthias Blamont, Michael Shields and Ben Hirschler
Source: Reuters
Politico’s Agency IQ reported earlier this month that, due to the Trump administration’s laying off of thousands of staffers, the FDA risked hitting a “trigger,” whereby the FDA could be required to refund industry fees if spending by the agency falls below a certain level.
Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump “threaten” billions of planned pharma investments on the continent. A group of 32 pharma companies sent a letter to European Commission (EC) President Ursula von der Leyen listing requests to avoid an exodus of operations.
Christian Boehringer, Chairman of the Shareholders’ Committee since 2007, has decided to step down from his position as of June 30, 2025. The Shareholders’ Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor from July 1, 2025.
